PMID- 19696636
OWN - NLM
STAT- MEDLINE
DCOM- 20090917
LR  - 20231213
IS  - 1534-6080 (Electronic)
IS  - 0041-1337 (Linking)
VI  - 88
IP  - 4
DP  - 2009 Aug 27
TI  - Clinical significance of HLA-E*0103 homozygosity on survival after allogeneic 
      hematopoietic stem-cell transplantation.
PG  - 528-32
LID - 10.1097/TP.0b013e3181b0e79e [doi]
AB  - BACKGROUND: Hematopoietic stem-cell transplantation is a well-established 
      treatment in various hematologic malignancies, but the outcome depends on disease 
      relapse, infections, and the development and severity of acute and chronic 
      graft-versus-host disease. Some evidence has revealed an important role for the 
      nonclassical major histocompatibility complex class I molecules in 
      transplantation, most notably human leukocyte antigen (HLA)-E. This study 
      evaluates the impact of HLA-E alleles on transplantation outcome after 
      HLA-matched allogeneic HSCT. METHODS: We genotyped DNA for HLA-E polymorphism 
      from 83 recipients and their respective donors by real-time polymerase chain 
      reaction after melting curve analysis and compared the results with clinical 
      outcome. RESULTS: HLA-E*0103 homozygous patients showed a higher probability of 
      overall survival (P=0.003) and disease-free survival (P=0.001) in a univariate 
      model. Cox regression analysis confirmed HLA-E*0103, 0103 (P=0.006; relative risk 
      1.12; 95% confidence interval 0.31-1.94) and early stage of disease (P=0.005; 
      relative risk 1.16; 95% confidence interval 0.45-1.86) as independent factors 
      improving overall survival. Moreover, homozygosity for HLA-E*0103 was associated 
      with a significant decreased incidence of transplant-related mortality (P=0.01). 
      CONCLUSIONS: We found an association between HLA-E*0103 homozygosity and the 
      significant reduction of transplant-related mortality in related and unrelated 
      HSCT. The risk of posttransplant complications was significantly reduced when the 
      donor possesses the HLA-E*0103, 0103 genotype, and this was translated in a 
      better overall survival.
FAU - Danzer, Martin
AU  - Danzer M
AD  - Red Cross Transfusion Service of Upper Austria, Linz, Austria. 
      martin.danzer@o.roteskreuz.at
FAU - Polin, Helene
AU  - Polin H
FAU - Proll, Johannes
AU  - Proll J
FAU - Haunschmid, Reinhard
AU  - Haunschmid R
FAU - Hofer, Katja
AU  - Hofer K
FAU - Stabentheiner, Stephanie
AU  - Stabentheiner S
FAU - Hackl, Christa
AU  - Hackl C
FAU - Kasparu, Hedwig
AU  - Kasparu H
FAU - Konig, Josef
AU  - Konig J
FAU - Hauser, Hanns
AU  - Hauser H
FAU - Binder, Michaela
AU  - Binder M
FAU - Weiss, Richard
AU  - Weiss R
FAU - Gabriel, Christian
AU  - Gabriel C
FAU - Krieger, Otto
AU  - Krieger O
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Transplantation
JT  - Transplantation
JID - 0132144
RN  - 0 (DNA Primers)
RN  - 0 (HLA Antigens)
RN  - 0 (Histocompatibility Antigens Class I)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Base Sequence
MH  - Cohort Studies
MH  - DNA Primers/genetics
MH  - Female
MH  - Genotype
MH  - Graft vs Host Disease/genetics/immunology
MH  - HLA Antigens/*genetics
MH  - *Hematopoietic Stem Cell Transplantation/adverse effects/mortality
MH  - Heterozygote
MH  - Histocompatibility Antigens Class I
MH  - Homozygote
MH  - Humans
MH  - Kaplan-Meier Estimate
MH  - Male
MH  - Middle Aged
MH  - Transplantation, Homologous
MH  - Young Adult
MH  - HLA-E Antigens
EDAT- 2009/08/22 09:00
MHDA- 2009/09/18 06:00
CRDT- 2009/08/22 09:00
PHST- 2009/08/22 09:00 [entrez]
PHST- 2009/08/22 09:00 [pubmed]
PHST- 2009/09/18 06:00 [medline]
AID - 00007890-200908270-00013 [pii]
AID - 10.1097/TP.0b013e3181b0e79e [doi]
PST - ppublish
SO  - Transplantation. 2009 Aug 27;88(4):528-32. doi: 10.1097/TP.0b013e3181b0e79e.